Advanced Biomedical Technologies Inc.: directors' dealings · United States · SEC (Form 4)

About Advanced Biomedical Technologies Inc.

Advanced Biomedical Technologies Inc. is a U.S.-based medical technology company focused on orthopedic internal fixation devices. For French-, Belgian- and Swiss-based investors, it should be viewed as a very small-cap healthcare name with the liquidity, disclosure depth, and execution risk typically associated with OTC-listed issuers rather than with a large NYSE or NASDAQ blue-chip listing. Public company profiles place the business in New York, United States, and indicate that the company’s modern operating history dates back to the mid-2000s; some databases differ on the exact founding year, so the most prudent characterization is that it was established in the 2000s. ([linkedin.com](https://www.linkedin.com/company/advanced-biomedical-technologies-inc?utm_source=openai)) The company’s core business appears to center on the development and commercialization of orthopedic internal fixation products, especially proprietary polymer-based implants and screws made from high-grade polyamide (“PA”). Its product set is aimed at applications in orthopedic trauma, sports-related injuries, cartilage damage, and reconstructive dental procedures. Management has positioned these products as resorbable alternatives to metal implants and as solutions intended to overcome limitations of other absorbable fixation materials, with the stated objective of supporting new bone growth during healing. ([linkedin.com](https://www.linkedin.com/company/advanced-biomedical-technologies-inc?utm_source=openai)) From a competitive standpoint, Advanced Biomedical Technologies operates in a highly specialized niche of the medical device market. That can be strategically attractive if the technology gains clinical acceptance, because niche orthopedic and dental fixation products can create differentiated value propositions. At the same time, the company’s scale is far smaller than that of global medtech peers, which likely constrains commercial reach, manufacturing scale, and negotiating power with distributors and healthcare buyers. Publicly available sources also suggest a limited employee base and a predominantly U.S. footprint, with headquarters in New York and no clear evidence of a broad international commercial platform. ([linkedin.com](https://www.linkedin.com/company/advanced-biomedical-technologies-inc?utm_source=openai)) Recent publicly visible activity is mainly tied to SEC disclosure rather than major headline operating news. The company has reported insider transactions through SEC Form 4 filings, confirming that it remains subject to standard U.S. reporting obligations for officers and directors. Insider-trading tracking sources also point to a thin trading history and a very small market capitalization profile, which are important risk markers for investors. In investment terms, this is best described as a speculative healthcare micro-cap whose valuation case depends on whether its technology can translate into commercial adoption, regulatory progress, and sustainable operating momentum. ([fintel.io](https://fintel.io/sn/us/abmt?utm_source=openai))